| Name | Title | Contact Details |
|---|
Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies. Our mission is to understand the science of developing drug products with unique attributes, bring to market products that add value to our patients and customers, and provide a benefit to our company, employees and society at large.
Mcnan Technologies Inc is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tarveda Therapeutics is a clinical stage biopharmaceutical company that takes a novel approach to cancer treatment by creating proprietary Pentarins, which are potent and selective, miniaturized conjugates uniquely designed to drive efficacy through deep and rapid penetration into solid tumors resulting in sustained payload accumulation and cancer cell death. Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors.
Immatics Biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. Cancer immunotherapy is still severely constrained by the lack of novel targets. Immatics overcomes this by applying its target discovery engine XPRESIDENT® to identify and validate antigens specific to cancer cells. These antigens, also called Tumor-Associated Peptides (TUMAPs), are able to activate T cells which are responsible for identifying and destroying cancer cells. These well characterized TUMAPs can be used as targets for all of the most promising cancer immunotherapy approaches including Adoptive Cell Therapies (ACT), soluble T Cell Receptors (TCRs), Antibodies and Cancer Vaccines. The US based Immatics US, Inc., launched in Aug. 2015, is focused on the development of three ACT approaches for the treatment of tumors with high unmet medical needs: ACTolog™, ACTengine™, and ACTallo™ in close collaboration with leading scientists at the MD Anderson Cancer Center, who contribute their long-term ACT expertise. The first ACT products are expected to enter the clinic in 2016. Immatics signed a strategic cancer immunotherapy collaboration with Roche in November 2013 to research, develop and commercialize a number of new cancer peptide antigen-based immunotherapies. In addition, Immatics is engaged in the development of soluble T-cell receptor (sTCR) approaches as well as monoclonal antibodies (mABs) directed towards XPRESIDENT® targets. The latter will be pursued in a strategic alliance with MorphoSys. Immatics is further conducting the clinical development of fully personalized therapeutic cancer vaccines, Glioma Actively Personalized VAccine Consortium (GAPVAC; an EU-funded consortium) in collaboration with BioNTech. Immatics GmbH is based in Tübingen, Germany, with a headcount of approximately 90 people. Immatics US, Inc. is based in Houston, Texas, USA, and currently employs approximately 15 people.
Gradientech is developing the microfluidic platform of tomorrow, today. Our revolutionising in vitro diagnostic system, QuickMIC®, is designed to strengthen labs by providing reliable results, at outstanding speed. Visit to experience how.